The Food and Drug Administration has recently released new provider information to assist in prescribing Paxlovid for treatment of mild to moderate COVID-19. The AMA is sharing this information at the request of the FDA Commissioner to assist in increasing the use of Paxlovid for the treatment of COVID-19-positive patients. The information provides clarity around patient eligibility for Paxlovid and includes a patient eligibility screening checklist for use by prescribers. It also includes guidance on managing drug-drug interactions with Paxlovid.